ArticleBMC research notes2016
Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists.
Article in BMC research notes, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 61 citations in OpenAlex.
- Predictive modeling and clinical decision tools for risk stratification in steatotic liver disease.Clinical and molecular hepatology · 2026Review
- Towards a Better Understanding of MASLD: Patient Health Literacy, Illness Perception, and Awareness.Diseases (Basel, Switzerland) · 2026Article
- Microvascular complications of type 2 diabetes with or without MASLD: the EPSOMIP study, a primary care cohort study.BMC primary care · 2025Observational
- Cross-sectional Study of Resident Physician Knowledge and Perceptions Regarding MASLD in Canada.Canadian liver journal · 2025Article
- Practice Recommendations for the Management of MASLD in Primary Care: Consensus Results.Diseases (Basel, Switzerland) · 2024Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective.Journal of clinical medicine · 2023Review
- A global survey of health care workers' awareness of non-alcoholic fatty liver disease: The AwareNASH survey.United European gastroenterology journal · 2023Article
- Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Screening, Diagnosis, and Treatment.Journal of clinical medicine · 2023Review
- Comparison between metabolic-associated fatty liver disease and nonalcoholic fatty liver disease: From nomenclature to clinical outcomes.World journal of hepatology · 2023Review
- CT-based Hounsfield unit values reflect the degree of steatohepatitis in patients with low-grade fatty liver disease.BMC gastroenterology · 2023Article
- Development and implementation of a continuing medical education program on non-alcoholic fatty liver disease for primary care practitioners in Europe.Frontiers in medicine · 2023Article
- Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name.Clinical and molecular hepatology · 2022Review
- The Association of Fibrosis-4 Index Scores with Severe Liver Outcomes in Primary Care.Journal of general internal medicine · 2022Article
- Awareness, management, and practice patterns of pediatric NAFLD by primary care physicians.Paediatrics & child health · 2022Article
- Differences in NAFLD/NASH Management by Provider Specialty: Opportunities for Optimizing Multidisciplinary Care.Journal of multidisciplinary healthcare · 2022Article
- Underrecognition of Nonalcoholic Fatty Liver Disease in Poorly Controlled Diabetes: A Call to Action in Diabetes Care.Journal of the Endocrine Society · 2021Article
- Advanced liver fibrosis and the metabolic syndrome in a primary care setting.Diabetes/metabolism research and reviews · 2021Article
- Dietary Regulation of Oxidative Stress in Chronic Metabolic Diseases.Foods (Basel, Switzerland) · 2021Review
- Cross-sectional pilot study to assess primary healthcare workers' knowledge of nonalcoholic fatty liver disease in a marginalized community in Mexico.Scientific reports · 2021Article
- Insights from qualitative research on NAFLD awareness with a cohort of T2DM patients: time to go public with insulin resistance?BMC public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe hepatic manifestation of metabolic syndrome is nonalcoholic fatty liver disease. Patients with nonalcoholic steatohepatitis, the progressive form of nonalcoholic fatty liver disease, have increased risk of fibrosis, cirrhosis and end-stage liver disease. Estimates of prevalence in the United States range from 20-30% for nonalcoholic fatty liver disease and 2-5% for nonalcoholic steatohepatitis; however, physician awareness of these diseases is limited. The purpose of this study was to determine the current level of physician awareness and practices in the diagnosis and management of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis within the United States.
methodsPhysicians were asked to participate in an online, 35-question survey about their awareness of various liver conditions and current practices.
resultsOf the 302 responding physicians, 152 were primary care physicians, and 150 were specialists (comprised of gastroenterologists and hepatologists). More specialists than primary care physicians reported that they were aware of the differences between nonalcoholic fatty liver disease and nonalcoholic steatohepatitis (p < 0.001) and that they routinely screened for nonalcoholic fatty liver disease (p < 0.001) and nonalcoholic steatohepatitis (p < 0.001). Almost half of the responding primary care physicians reported being unfamiliar with the nonalcoholic fatty liver disease and nonalcoholic steatohepatitis differences even though they were aware of both, yet 58% of those primary care physicians were treating patients with nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis. In addition, those primary care physicians who reported being unfamiliar with nonalcoholic steatohepatitis were treating an average of 3.7 patients and reported being as likely as familiar primary care physicians to treat new patients with nonalcoholic steatohepatitis. More than half of the specialists used noninvasive diagnostic test to confirm nonalcoholic steatohepatitis, and 10% of the specialists reported treating patients with drugs not recommended by the current guidelines.
conclusionsDespite reporting they were not familiar with nonalcoholic steatohepatitis, primary care physicians reported they would likely continue to diagnose and manage patients with nonalcoholic steatohepatitis; therefore, more physician education on the recent practice guideline for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis is needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.